GOVERNMENT OF INDIA
MINISTRY OF AYURVEDA, YOGA & NATUROPATHY,
UNANI, SIDDHA AND HOMOEOPATHY
(AYUSH)

LOK SABHA
UNSTARRED QUESTION NO.913
TO BE ANSWERED ON 23RD JULY, 2021

DISTRIBUTION OF AYUSH-64

913. DR. SANJEEV KUMAR SINGARI:
SHRI P.V. MIDHUN REDDY:

Will the Minister of AYUSH be pleased to state:

(a) whether the Government has taken any initiatives to streamline the distribution of AYUSH-64 across the country if so, the details thereof;

(b) whether the Government is encouraging more pharmaceutical companies to come forward and obtain a manufacturing license for AYUSH-64 and if so, the details thereof;

(c) whether the Central Council for Research in Ayurvedic Sciences (CCRAS) and National Research and Development Centre (NRDC) have signed an MoU for the larger production and commercialization of AYUSH 64, if so, the details thereof;

(d) whether the Government had issued advisory to all State Licensing Authorities of ASU medicines to repurpose AYUSH-64 as an intervention for the management of mild to moderate COVID-19 in addition to existing indications; and

(e) if so, the details thereof?

ANSWER
THE MINISTER OF STATE OF THE MINISTRY OF AYURVEDA,
YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY
(DR. MUNJPARA MAHENDRABHAI)

(a): The Government of India has launched a nation-wide campaign through its Research Councils and National Institutes for mass distribution of AYUSH-64 to asymptomatic, mild to moderate COVID-19 patients in home isolation. AYUSH-64 has been distributed to approximately 58000 COVID-19 patients.

(b): The Central Council of Research in Ayurvedic Sciences (CCRAS), an autonomous Organization under the aegis of Ministry of AYUSH, has issued a Notification, dated 30.04.2021, regarding commercialization of AYUSH-64, through National Research Development Corporation (NRDC). So far AYUSH-64 technology has been transferred to 29 pharmaceutical companies.

(c): The CCRAS and NRDC have signed an MoU dated 3rd March 2015 for the purpose of commercialization of Technologies and IPR generated by CCRAS, including AYUSH-64, by NRDC.
(d) & (e): The regulatory and quality control provisions for the manufacturing of AYUSH drugs/medicines under “Drugs and Cosmetics Act, 1940 and Rules” there under, are enforced by the Licensing Authorities/Drug Controllers appointed by the State/UT Government. Therefore, all the State AYUSH Licensing Authorities/Drug Controller and Expert Committees there under, have been informed to allow the licensed manufacturers for AYUSH-64 under their jurisdiction, to include new indication of AYUSH-64 for repurposing as an intervention for the management of asymptomatic, mild to moderate COVID-19, in addition to existing indication(s).